Evaluation of bacteriophage therapy to control Clostridium difficile and toxin production in an in vitro human colon model system

被引：70
作者：
Meader, Emma [1 ,2 ]
Mayer, Melinda J. [1 ]
Steverding, Dietmar [2 ]
Carding, Simon R. [1 ,2 ]
Narbad, Arjan [1 ]
机构：
[1] Inst Food Res, Gut Hlth & Food Safety Inst, Strateg Programme, Norwich NR4 7UA, Norfolk, England
[2] Univ E Anglia, Norwich Med Sch, Norwich NR4 7TJ, Norfolk, England
来源：
ANAEROBE | 2013年 / 22卷
基金：
英国生物技术与生命科学研究理事会;
关键词：
Clostridium difficile; Bacteriophage therapy; Human colon model; Toxin; Lysogeny; HUMAN GUT MODEL; MOLECULAR CHARACTERIZATION; METRONIDAZOLE; VANCOMYCIN; INFECTION; DIVERSITY; PHAGES;
D O I：
10.1016/j.anaerobe.2013.05.001
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
Clostridium difficile is a leading cause of hospital-acquired diarrhoea and represents a major challenge for healthcare providers. Due to the decreasing efficacy and associated problems of antibiotic therapy there is a need for synergistic and alternative treatments. In this study we investigated the use of a specific bacteriophage, Phi CD27, in a human colon model of C difficile infection. Our findings demonstrate a significant reduction in the burden of C difficile cells and toxin production with phage treatment relative to an untreated control, with no detrimental effect on commensal bacterial populations. The results demonstrate the potential of phage therapy, and highlight the limitations of using phages that have lysogenic capacity. (C) 2013 Elsevier Ltd. All rights reserved.
引用
收藏
页码：25 / 30
页数：6
相关论文
共 30 条
  • [21] Evaluation of protective effect of Lactobacillus acidophilus La-5 on toxicity and colonization of Clostridium difficile in human epithelial cells in vitro
    Najarian, A.
    Sharif, S.
    Griffiths, M. W.
    ANAEROBE, 2019, 55 : 142 - 151
  • [22] Persistence and Toxin Production by Clostridium difficile within Human Intestinal Organoids Result in Disruption of Epithelial Paracellular Barrier Function
    Leslie, Jhansi L.
    Huang, Sha
    Opp, Judith S.
    Nagy, Melinda S.
    Kobayashi, Masayuki
    Young, Vincent B.
    Spence, Jason R.
    INFECTION AND IMMUNITY, 2015, 83 (01) : 138 - 145
  • [23] Effect of Clostridium difficile toxin A on human intestinal epithelial cells: Induction of interleukin 8 production and apoptosis after cell detachment
    Mahida, YR
    Makh, S
    Hyde, S
    Gray, T
    Borriello, SP
    GUT, 1996, 38 (03) : 337 - 347
  • [24] Co-amoxiclav induces proliferation and cytotoxin production of Clostridium difficile ribotype 027 in a human gut model
    Chilton, Caroline H.
    Freeman, Jane
    Crowther, Grace S.
    Todhunter, Sharie L.
    Nicholson, Scott
    Wilcox, Mark H.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2012, 67 (04) : 951 - 954
  • [25] Zur Pathogenese der Antibiotikakolitis: Wirkung von Clostridium difficile Toxin A und B auf die humane Kolonschleimhaut in vitroAntibiotic-associated colitis: Effect of clostridium difficile toxins A and B on human colonic mucosa in vitro
    M. Riegler
    R. Sedivy
    Ch. Pothoulakis
    B. Teleky
    G. H. Hamilton
    J. Zacherl
    G. Bischof
    E. Cosentini
    J. Th. LaMont
    E. Wenzl
    Acta chirurgica Austriaca, 1997, 29 (2) : 95 - 101
  • [26] Efficacy of vancomycin extended-dosing regimens for treatment of simulated Clostridium difficile infection within an in vitro human gut model
    Crowther, Grace S.
    Chilton, Caroline H.
    Longshaw, Chris
    Todhunter, Sharie L.
    Ewin, Duncan
    Vernon, Jonathan
    Karas, Andreas
    Wilcox, Mark H.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2016, 71 (04) : 986 - 991
  • [27] THE PRODUCTION OF CLOSTRIDIUM-DIFFICILE (CD) TOXIN-A AND TOXIN-B CAN BE MODULATED BY NON ANTIBIOTIC DRUGS AS PHENOTHIAZINES AND METHOTREXATE INVIVO IN GNOTOBIOTIC MICE CARRYING A COMPLEX HUMAN MICROFLORA
    BARC, MC
    DEPITRE, C
    CORTHIER, G
    BOURLIOUX, P
    MEDECINE ET MALADIES INFECTIEUSES, 1990, 20 : 71 - 74
  • [28] A Combination of Three Fully Human Toxin A- and Toxin B-Specific Monoclonal Antibodies Protects against Challenge with Highly Virulent Epidemic Strains of Clostridium difficile in the Hamster Model
    Anosova, Natalie G.
    Cole, Leah E.
    Li, Lu
    Zhang, Jinrong
    Brown, Anna M.
    Mundle, Sophia
    Zhang, Jianxin
    Ray, Satyajit
    Ma, Fuqin
    Garrone, Pierre
    Bertraminelli, Nicola
    Kleanthous, Harry
    Anderson, Stephen F.
    CLINICAL AND VACCINE IMMUNOLOGY, 2015, 22 (07) : 711 - 725
  • [29] Development of Clostridium difficile R20291ΔPaLoc model strains and in vitro methodologies reveals CdtR is required for the production of CDT to cytotoxic levels
    Bilverstone, T. W.
    Kinsmore, N. L.
    Minton, N. P.
    Kuehne, S. A.
    ANAEROBE, 2017, 44 : 51 - 54
  • [30] Novel Clostridium difficile Anti-Toxin (TcdA and TcdB) Humanized Monoclonal Antibodies Demonstrate In Vitro Neutralization across a Broad Spectrum of Clinical Strains and In Vivo Potency in a Hamster Spore Challenge Model
    Qiu, Hongyu
    Cassan, Robyn
    Johnstone, Darrell
    Han, Xiaobing
    Joyee, Antony George
    McQuoid, Monica
    Masi, Andrea
    Merluza, John
    Hrehorak, Bryce
    Reid, Ross
    Kennedy, Kieron
    Tighe, Bonnie
    Rak, Carla
    Leonhardt, Melanie
    Dupas, Brian
    Saward, Laura
    Berry, Jody D.
    Nykiforuk, Cory L.
    PLOS ONE, 2016, 11 (06):
123